Biomarin Pharmaceutical Inc (BMRN)
91.41
-0.09
(-0.10%)
USD |
NASDAQ |
Mar 28, 16:00
91.41
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 17.05B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 15.79% |
| Valuation | |
| PE Ratio | 123.75 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.220 |
| Price to Book Value | 3.704 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2353 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 56.90% |
News
Headline
Wire
Time (ET)
Yahoo
03/28 06:38
MT Newswires
03/27 16:08
SA Breaking News
03/24 15:00
MT Newswires
03/21 07:34
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 04/27/2023* | -- | Results | Q1 2023 | -- | 0.46 | -- | |
| 04/27/2023* | 13:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 02/27/2023 | -- | Results | Q4 2022 | 0.36 | 0.39 | -7.10% | |
| 02/27/2023 | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 10/26/2022 | -- | Results | Q3 2022 | 0.45 | 0.43 | 4.85% | |
| 10/26/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | 0.58 | 0.53 | 9.49% | |
| 08/03/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and is poised for U.S. approval in 2023. |
| URL | http://www.bmrn.com |
| Investor Relations URL | https://investors.biomarin.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Apr. 27, 2023 (est.) |
| Last Earnings Release | Feb. 27, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 27, 2023.
Fundamentals
| Revenue (TTM) | 2.096B |
| Total Expenses (TTM) | 2.054B |
| Net Income (TTM) | 141.56M |
| Total Assets (Quarterly) | 6.375B |
| Total Liabilities (Quarterly) | 1.772B |
| Shareholders Equity (Quarterly) | 4.603B |
| Cash from Operations (TTM) | 175.90M |
| Cash from Investing (TTM) | -20.03M |
| Cash from Financing (TTM) | -18.65M |
Ratings
Profile
Edit
| BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and is poised for U.S. approval in 2023. |
| URL | http://www.bmrn.com |
| Investor Relations URL | https://investors.biomarin.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Apr. 27, 2023 (est.) |
| Last Earnings Release | Feb. 27, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| PBE | 11.05M USD | 4.49% |
| VHCOX | 599.57M USD | 3.27% |
| POAGX | 198.35M USD | 3.08% |
| BBH | 15.08M USD | 3.08% |
| POGRX | 173.46M USD | 2.62% |
| BMEZ | 36.36M USD | 1.83% |
| IBB | 127.97M USD | 1.61% |
| VAFNX | 155.43M USD | 1.42% |
| SCHM | 44.53M USD | 0.49% |
| FSMAX | 109.71M USD | 0.33% |
| VEXMX | 252.52M USD | 0.29% |
| VXF | 252.52M USD | 0.29% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| BMRN Tweets |